Source: Citybizlist

OncoSec: OncoSec Prices of $3.5 Million Public Offering

OncoSec Medical Incorporated (NASDAQ: ONCS), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune... Read MoreThe post OncoSec Prices of $3.5 Million Public Offering appeared first on citybiz.

Read full article »

OncoSec's Competitors | OncoSec's News | OncoSec's Financials

Followers on Owler

Annual Revenue

$25-100M

Employees

25-100

President & CEO

Robert H. Arch

CEO Approval Rating

84/100

OncoSec is a New Jersey-based clinical-stage biotechnology company that researches and develops intratumoral immunotherapies for the treatment of cancer.